Glaukos (GKOS)
(Delayed Data from NYSE)
$99.48 USD
-0.63 (-0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $99.49 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GKOS 99.48 -0.63(-0.63%)
Will GKOS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GKOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GKOS
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) Gains Nearly 25% YTD: What's Driving the Rally?
GKOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
Glaukos' (GKOS) iDose TR Receives Permanent J- Code From CMS
Glaukos (GKOS) Down 4.3% Since Last Earnings Report: Can It Rebound?
Other News for GKOS
Glaukos Announces the Release of its 2023 Sustainability Report
Glaukos price target raised by $5 at BTIG, here's why
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Glaukos price target raised by $15 at Mizuho, here's why
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1